A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical trial NCT03670901 · TERMINATED
Trial details
- NCT number
- NCT03670901
- Sponsor
- JHL Biotech, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-13
- Primary completion
- 2019-03-07
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.